TFEB Antibody (S1)

ELISA: TFEB Antibody (S1) [H00007942-M01]

ELISA: TFEB Antibody (S1) [H00007942-M01] - TFEB Antibody (3E1-G6) [H00007942-M01] - Detection limit for recombinant GST tagged TFEB is approximately 0.03ng/ml as a capture antibody.

Western Blot: TFEB Antibody (S1) [H00007942-M01] -

Western Blot: TFEB Antibody (S1) [H00007942-M01] - GDF11 inhibits TFEB activity. (a) AML‐12 cells were cultured for 48 h in presence of GDF11 (100 ng/ml). qRT‐PCR analysis of the mRNA levels of TFEB & its target genes VPS11 & ATP6V1H. (b) AML‐12 cells transient expressing GFP‐TFEB were cultured for 48 h in presence of GDF11 (100 ng/ml). Immunofluorescence confocal microscopy showing TFEB localization with or without GDF11 (original magnification, 400×). (c) Nuclear TFEB fluorescence intensity normalized to vehicle controls. (d) Western blot analysis of total TFEB protein expression. (e) Densitometry analysis of the total TFEB. (f) Western blot analysis of nuclear TFEB protein expression. (g) Densitometry analysis of the nuclear TFEB. The experiment was performed in triplicate with similar results. The data are shown as mean ± SD, *p < 0.05 compared to the vehicle group Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/34905649), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: TFEB Antibody (S1) [H00007942-M01] -

Western Blot: TFEB Antibody (S1) [H00007942-M01] - TFEB expression reduces PHF1 levels in the P301S model of tauopathy, & significantly attenuates the loss of neuronal & synaptic markers in the hippocampus. A, Lysates were prepared from the hippocampal regions of WT, P301S, & P301S/flag-TFEB mice, & were subjected to immunoblotting. B, Quantitation by ImageJ revealed PHF1 levels of 436% in the P301S mice compared with WT controls, which were significantly attenuated to 212% in the P301S/flag-TFEB double-transgenic mice. However, TFEB expression did not alter the levels of total tau, which remained similar in the P301S & the double-transgenic mice. NeuN levels were reduced by 25% in the P301S mice, which was significantly reversed to WT levels in the double-transgenic mice. Similarly, spinophilin levels were reversed from 40% reduction to 6% due to TFEB overexpression. TFEB expression also increased LAMP1 levels by 207% & cathepsin D levels by 33% in the P301S/flag-TFEB mice compared with WT controls. Statistical analysis by one-way ANOVA followed by Student–Newman–Keuls post hoc test revealed significant differences. *p < 0.05, **p < 0.01, & ***p < 0.001, compared with WT controls; $$p < 0.01, $$$p < 0.001, compared with P301S mice. The data are reported as the mean ± SEM. n = 4 WT mice; n = 5 P301S & P301S/flag-TFEB mice. Image collected & cropped by CiteAb from the following publication (https://www.eneuro.org/lookup/doi/10.1523/ENEURO.0042-16.2016), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: TFEB Antibody (S1) [H00007942-M01] -

Western Blot: TFEB Antibody (S1) [H00007942-M01] - GDF11 inhibits TFEB activity. (a) AML‐12 cells were cultured for 48 h in presence of GDF11 (100 ng/ml). qRT‐PCR analysis of the mRNA levels of TFEB & its target genes VPS11 & ATP6V1H. (b) AML‐12 cells transient expressing GFP‐TFEB were cultured for 48 h in presence of GDF11 (100 ng/ml). Immunofluorescence confocal microscopy showing TFEB localization with or without GDF11 (original magnification, 400×). (c) Nuclear TFEB fluorescence intensity normalized to vehicle controls. (d) Western blot analysis of total TFEB protein expression. (e) Densitometry analysis of the total TFEB. (f) Western blot analysis of nuclear TFEB protein expression. (g) Densitometry analysis of the nuclear TFEB. The experiment was performed in triplicate with similar results. The data are shown as mean ± SD, *p < 0.05 compared to the vehicle group Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/34905649), licensed under a CC-BY license. Not internally tested by Novus Biologicals.